2型糖尿病患者炎症与氧化还原标志物对下肢动脉病变风险的预后价值
在SURDIAGENE队列1412例2型糖尿病患者中,基线血浆TNFR1和IMA高浓度与随访5.6年主要下肢动脉病变风险独立相关。TNFR1可提供传统风险因素之外的增量预后信息。
要点
- 基线血浆TNFR1第三分位较第一分位主要LEAD风险HR 2.16(95%CI 1.19-3.92,P=0.01)。
- 基线血浆IMA第二分位较第一分位HR 2.42(95%CI 1.38-4.23,P=0.002)。
- TNFR1在传统风险因素之上提供增量信息,C统计量变化0.036(P=0.002)。
核心结论
- 高血浆TNFR1或IMA浓度与2型糖尿病患者5.6年主要LEAD风险升高独立相关。
- TNFR1可提供增量预后信息,提示其可作为LEAD生物标志物。
研究设计与样本
- SURDIAGENE(Survie, Diabete de type 2 et Genetique)队列研究。
- 基线共纳入1412例2型糖尿病患者,男性58.2%,平均(SD)年龄64.7(10.6)岁,随访5.6年。
- 基线检测血浆TNFR1、血管生成素样蛋白2、缺血修饰白蛋白(IMA)、荧光晚期糖基化终产物、蛋白羰基及血浆总还原能力。
- 主要LEAD定义为随访期间发生外周血运重建或下肢截肢。
主要发现
- 随访期间112例(7.9%)发生主要LEAD。
- TNFR1第二分位较第一分位主要LEAD风险HR 1.12(95%CI 0.62-2.03,P=0.71),第三分位较第一分位HR 2.16(95%CI 1.19-3.92,P=0.01)。
- IMA第二分位较第一分位HR 2.42(95%CI 1.38-4.23,P=0.002),第三分位较第一分位HR 2.04(95%CI 1.17-3.57,P=0.01)。
- TNFR1在传统风险因素之上提供增量信息:C统计量变化0.036(95%CI 0.013-0.059,P=0.002),IDI 0.012(95%CI 0.005-0.022,P<0.001),连续NRI 0.583(95%CI 0.294-0.847,P<0.001),分类NRI 0.171(95%CI 0.027-0.317,P=0.02)。
- IMA未提供增量信息。
临床怎么用
- 在2型糖尿病患者中,可检测基线血浆TNFR1浓度以辅助LEAD风险分层。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Inflammation and oxidative stress play an important role in the pathogenesis of lower-extremity artery disease (LEAD). We assessed the prognostic values of inflammatory and redox status biomarkers on the risk of LEAD in individuals with type 2 diabetes. RESEARCH DESIGN AND METHODS: Plasma concentrations of tumor necrosis factor-α receptor 1 (TNFR1), angiopoietin-like 2, ischemia-modified albumin (IMA), fluorescent advanced glycation end products, protein carbonyls, and total reductive capacity of plasma were measured at baseline in the SURDIAGENE (Survie, Diabete de type 2 et Genetique) cohort. Major LEAD was defined as the occurrence during follow-up of peripheral revascularization or lower-limb amputation. RESULTS: Among 1,412 participants at baseline (men 58.2%, mean [SD] age 64.7 [10.6] years), 112 (7.9%) developed major LEAD during 5.6 years of follow-up. High plasma concentrations of TNFR1 (hazard ratio [95% CI] for second vs. first tertile 1.12 [0.62-2.03; P = 0.71] and third vs. first tertile 2.16 [1.19-3.92; P = 0.01]) and of IMA (2.42 [1.38-4.23; P = 0.002] and 2.04 [1.17-3.57; P = 0.01], respectively) were independently associated with an increased risk of major LEAD. Plasma concentrations of TNFR1 but not IMA yielded incremental information, over traditional risk factors, for the risk of major LEAD as follows: C-statistic change (0.036 [95% CI 0.013-0.059]; P = 0.002), integrated discrimination improvement (0.012 [0.005-0.022]; P < 0.001), continuous net reclassification improvement (NRI) (0.583 [0.294-0.847]; P < 0.001), and categorical NRI (0.171 [0.027-0.317]; P = 0.02). CONCLUSIONS: Independent associations exist between high plasma TNFR1 or IMA concentrations and increased 5.6-year risk of major LEAD in people with type 2 diabetes. TNFR1 allows incremental prognostic information, suggesting its use as a biomarker for LEAD.
引用
- Nativel M, Schneider F, Saulnier PJ, et al. Prognostic Values of Inflammatory and Redox Status Biomarkers on the Risk of Major Lower-Extremity Artery Disease in Individuals With Type 2 Diabetes. Diabetes Care. 2018. PMID: 30072406. doi:10.2337/dc18-0695
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。